Table 3 Patient clinicopathological data and HER-3, HER-4 expression
From: Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
| Â | HER- 3 expression (membranous or cytoplasmic) | HER- 4 expression (membranous or cytoplasmic) | ||||
|---|---|---|---|---|---|---|
Characteristic | (+) (n= 37) | (-) (n= 69) | p | (+) (n= 40) | (-) (n= 66) | p |
Age Median (range) | 65 (52 – 76) | 61 (35 – 79) | 0.009 | 64.5 (40 – 76) | 61 (35 – 79) | 0.189 |
Sex | ||||||
Male | 19 (51.4%) | 47 (68.1%) | 0.098 | 24 (60%) | 42 (63.6%) | 0.836 |
Female | 18 (48.6%) | 22 (31.9%) | Â | 16 (40%) | 24 (36.4%) | Â |
Size | 5 (2 – 12) | 5 (1.5 – 12) | 0.425 | 5 (2 – 12) | 5 (1.5 – 12) | 0.195 |
Lymph nodes status | ||||||
(+) | 25 (67.6%) | 44 (63.8%) | 0.999 | 33 (82.5%) | 36 (54.5%) | 0.010 |
(-) | 12 (32.4%) | 22 (31.9%) | Â | 7 (17.5%) | 27 (40.9%) | Â |
Grade | ||||||
Well | - | 3 (4.2%) | 0.550 | - | 3 (4.5%) | 0.288 |
Moderate | 37 (100%) | 58 (84.1%) | 0.008 | 37 (92.5%) | 58 (87.9%) | 0.529 |
Poor | - | 8 (11.6%) | 0.048 | 3 (7.5%) | 5 (7.6%) | 0.999 |
Dukes' stage | ||||||
B | 11 (29.7%) | 19 (27.5%) | 0.824 | 7 (17.5%) | 23 (34.8%) | 0.075 |
C | 18 (48.6%) | 33 (47.8%) | 0.999 | 20 (50%) | 31 (47%) | 0.842 |
D | 8 (21.6%) | 17 (24.6%) | 0.813 | 13 (32.5%) | 12 (18.2%) | 0.104 |
Site | ||||||
Proximal colon | 10 (27%) | 19 (27.5%) | 0.999 | 12 (30%) | 17 (25.8%) | 0.658 |
Distal colon | 13 (35.1%) | 24 (34.8%) | 0.999 | 14 (35%) | 23 (34.8%) | 0.999 |
Rectum | 14 (37.8%) | 26 (37.7%) | 0.999 | 26 (39.4%) | 14 (35%) | 0.684 |